No. AE Per Participant | Trial Arm, n | Total Participants, n | ||
---|---|---|---|---|
Lead-in | 25 mg | 50 mg | ||
0 | 11 | 1 | 0 | 12 |
1–5 | 8 | 7 | 9 | 24 |
6–10 | 3 | 7 | 5 | 15 |
11–15 | 2 | 2 | 2 | 6 |
16–20 | 0 | 1 | 0 | 1 |
21+ | 0 | 1 | 0 | 1 |
Total | 24 | 19 | 16 | 59 |
AE | Trial Arm, n | ||
---|---|---|---|
Lead-in | 25 mg | 50 mg | |
Infectious complications | 4 | 30 | 21 |
Injection site reaction | 5 | 16 | 9 |
Itching/skin rash | 1 | 4 | 1 |
Uveitis | 2 | 3 | 0 |